explore -WSS

explore

author：fashion 2025-09-30 18:34:43 - browse：2

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： 15 die by electrocution after transformer explodes in northern India

Wikipedia

WSS

15 die by electrocution after transformer explodes in northern India

White House drug shortages task force keeps mum with Congress

BridgeBio heart drug succeeds in pivotal study

Manchin plays down potential 3rd

Some of the ways extreme heat will change life as we know it

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

entertainment

explore

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

The history of OxyContin, told through Purdue Pharma documents

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Twill hunts for pharma partner to market its depression app

Drug repurposing or repositioning? The language matters

A look at other Americans who have crossed into North Korea over the years

Alkermes shareholders re

Some of the ways extreme heat will change life as we know it

Medical leaders decry Supreme Court decision on affirmative action

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

hotspot

Newly revealed memo details efforts to keep Trump in power following election loss

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Twill hunts for pharma partner to market its depression app

Novo acquires Inversago for up to $1 billion

Novo acquires Inversago for up to $1 billion

Novo acquires Inversago for up to $1 billion

focus

focus

Wikipedia

leisure time